Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hepatitis C × peginterferon alfa-2a × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Melanoma 1 Infections 1 Hepatitis C 1 Carcinoma, Hepatocellular 1

Interventions

telaprevir 1 peginterferon alfa-2a 1 hepatitis C immune globulin, human 1 elbasvir-grazoprevir drug combination 1 Ribavirin 1 Introns 1 Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated

1 enrolled 3 charts

Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡